Loading...
Market
How many countries will approve KarXT for schizophrenia treatment by the end of 2025?
2
Resolution / Starting Odds
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Official announcements from respective countries' health regulatory bodies
Story
KarXT by Bristol Myers Squibb: First Novel Schizophrenia Drug in 70 Years Shows 30% Symptom Improvement for 1 in 300 People
Oct 17, 2024, 12:00 PM
KarXT, a new oral medication developed by Bristol Myers Squibb (BMS), aims to be the first significant advancement in schizophrenia treatment in over 70 years. This twice-daily pill is designed to address the severe mental health condition that affects approximately 1 in 300 people globally. Early reports indicate that patients using KarXT are experiencing a 30% improvement in symptoms, while also avoiding the severe side effects commonly associated with older schizophrenia medications. The development of KarXT has been supported by research funded by the Wellcome Trust, highlighting the potential for pharmaceutical innovation to enhance treatment options for millions affected by this condition.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
< 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
> 30% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Yes • 50%
No • 50%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Negative impact • 25%
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
0 countries • 25%
1-5 countries • 25%
6-10 countries • 25%
More than 10 countries • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%